Search NLS News

Industry, academic, and public stakeholders will join forces in a new council aimed at accelerating the region's life science development.

Oncopeptides' clinical trial application for the "Window-of-Opportunity" (WoO) study in glioblastoma has been formally approved in Norway.

The orphan drug designation has been granted for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease.

The company has now received GMP (Good Manufacturing Practice) certification as well as manufacturing authorization from the Swedish Medical Products Agency for the production of biological investigational medicinal products for human use.

Herantis Pharma has announced a collaboration with Indivi, a Basel-based TechBio company focused on advancing precision medicine in neuroscience drug development, to integrate Indivi's digital biomarker platform into Herantis' upcoming Phase 2 proof-of-concept study of HER-096 in people living with Parkinson's disease.

Orexo has announced positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology.

The acquisition adds expertise and a next generation gene therapy platform to LEO Pharma’s pipeline through Replay’s high‑payload herpes simplex virus (HSV) delivery vector.

The company has been awarded funding through the program “Kompetensförstärkning i småföretag 2026.” The funding will support a new project focused on the development planning of a green, dual-use nebulization technology designed for delivery of MucoLife’s lead therapeutic candidate, MLT-001. MLT-001 is a first-in-class inhaled therapy being developed to rapidly dissolve pathological mucus plugs in […]

The company has received a patent in the United States for its mucoadhesive patch technology, M045A, developed for the treatment of recurrent aphthous stomatitis (mouth ulcers).

Hansa Biopharma and SERB S.A. have announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.